MITSUI CHEMICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,375.00 JPY | +1.78% |
|
+2.83% | -2.74% |
| Dec. 29 | Mitsui Chemicals Spends 2.16 Billion Yen in Share Repurchase | MT |
| Dec. 24 | Tranche Update on Mitsui Chemicals, Inc.'s Equity Buyback Plan announced on November 22, 2024. | CI |
Highlights: Mitsui Chemicals, Inc.
- The company's profit outlook over the next few years is a strong asset.
- Its low valuation, with P/E ratio at 10.1 and 7.82 for the ongoing fiscal year and 2026 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company shows low valuation levels, with an enterprise value at 0.66 times its sales.
- The company appears to be poorly valued given its net asset value.
- The company is one of the best yield companies with high dividend expectations.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses: Mitsui Chemicals, Inc.
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The group shows a rather high level of debt in proportion to its EBITDA.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings Chart: Mitsui Chemicals, Inc.
Source: Surperformance
ESG chart: Mitsui Chemicals, Inc.
Source: MSCI
| Composite Fundamentals | Composite Valuation | Composite Momentum | Capi. ($) | ||
|---|---|---|---|---|---|
| 3.95B | |||||
| 96.41B | |||||
| 54.46B | |||||
| 35.75B | |||||
| 29.16B | |||||
| 25.22B | |||||
| 16.82B | |||||
| 15.34B | |||||
| 14.15B | |||||
| 11.37B | |||||
| Average | 30.26B | ||||
| Weighted average by Cap. |
Investor Rating
Trading Rating
ESG MSCI
AA
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
ESG
Environment
Social
Governance
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 4183 Stock
- Ratings Mitsui Chemicals, Inc.